Back to results
US 2025/0085296 A1Published application
Generation of human allergen- and helminth-specific ige monoclonal antibodies for diagnostic and therapeutic use
AssigneeVanderbilt University
InventorScott A. SMITH
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.
Claims12
1-78. (canceled)
A method of generating a hydridoma that produces an IgE antibody comprising:
- (a) activating one or more peripheral blood mononuclear cells (PBMC's) with rh-IL-21, CD40L and BAFF;
- (b) screening the activated cell or cells of step (a) for IgE expression;
- (c) fusing one or more IgE-expressing PMBCs identified in step (b) with an immortal cell;
- (d) subjecting a fused cell or cells of step (c) to selection for a fusion event;
- (e) screening one or more selected fused cells of step (d) binding to an antigen;
- (f) cloning one or more selected fused cells positive for antigen binding;
- and
- (g) propagating one or more cloned cells of step (f).
5 more elements
89-125. (canceled)
Dependencies are inferred from the claim text.